What's Happening?
The Peterson Health Technology Institute released a report evaluating virtual solutions for opioid use disorder (OUD). The report found that virtual prescribing services for medications like buprenorphine are effective substitutes for in-person care but do not significantly expand access to treatment. Digital wraparound services provide incremental benefits but may not justify their cost. The report suggests that virtual prescribing should be allowed by the DEA, given its effectiveness.
Why It's Important?
The findings highlight the potential of virtual solutions to maintain treatment retention and offer cost savings. However, the lack of expanded access indicates a need for strategies to reach new patients and improve retention rates. The report's recommendations could influence regulatory decisions and the adoption of virtual care models in treating OUD.
What's Next?
The DEA is considering regulations for online prescribing of controlled substances, which could impact the future of virtual OUD treatment. The industry must explore new methods to increase access and retention, focusing on patient engagement and education.
Beyond the Headlines
The report underscores the importance of balancing cost and clinical benefits in adopting digital health solutions. It also highlights the need for comprehensive approaches to address the opioid crisis, beyond removing barriers to care.
